Want to see VTGN full AI Analyst Report?
VistaGen Therapeutics (VTGN) Stock Statistics & Valuation Metrics
Total Valuation
VistaGen Therapeutics has a market cap or net worth of $8.18M. The enterprise value is -$21.23M.
- Market Cap
- $8.18M
- Enterprise Value
- -$21.23M
Share Statistics
VistaGen Therapeutics has 44,376,910 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 44,376,910
- Owned by Insiders
- 0.26%
- Owned by Institutions
- 7.85%
Financial Efficiency
VistaGen Therapeutics’s return on equity (ROE) is -1.96 and return on invested capital (ROIC) is -197.26%.
- Return on Equity (ROE)
- -1.96
- Return on Assets (ROA)
- -1.43
- Return on Invested Capital (ROIC)
- -197.26%
- Return on Capital Employed (ROCE)
- -2.02
- Revenue Per Employee
- 30.95K
- Profits Per Employee
- -1.70M
- Employee Count
- 41
- Asset Turnover
- 0.03
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of VistaGen Therapeutics is -0.10. VistaGen Therapeutics’s PEG ratio is -0.02.
- PE Ratio
- -0.10
- PS Ratio
- 2.93
- PB Ratio
- 0.29
- Price to FCF
- -0.12
- Price to Operating Cash Flow
- -0.11
- PEG Ratio
- -0.02
Income Statement
In the last 12 months, VistaGen Therapeutics had revenue of 1.27M and earned -69.69M in profits. Earnings per share was -1.83.
- Revenue
- 1.27M
- Gross Profit
- 1.27M
- Operating Income
- -72.13M
- Pretax Income
- -69.68M
- Net Income
- -69.69M
- EBITDA
- -71.39M
- Earnings Per Share (EPS)
- -1.83
Cash Flow
In the last 12 months, operating cash flow was -62.30M and capital expenditures 0, giving a free cash flow of -62.30M billion.
- Operating Cash Flow
- -62.30M
- Free Cash Flow
- -62.30M
- Free Cash Flow per Share
- -1.45
Dividends & Yields
VistaGen Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -842.63%
- Earnings Yield
- -944.35%
Stock Price Statistics
- Beta
- 0.83
- 52-Week Price Change
- -96.05%
- 50-Day Moving Average
- 0.23
- 200-Day Moving Average
- 0.43
- Relative Strength Index (RSI)
- 29.49
- Average Volume (3m)
- 10.37M
Important Dates
VistaGen Therapeutics upcoming earnings date is Feb 11, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Nov 05, 2026
- Next Earnings Date
- Feb 11, 2027
- Ex-Dividend Date
- ―
Financial Position
VistaGen Therapeutics as a current ratio of 3.67, with Debt / Equity ratio of 2.94%
- Current Ratio
- 3.67
- Quick Ratio
- 3.67
- Debt to Market Cap
- 0.00
- Net Debt to EBITDA
- 0.42
- Interest Coverage Ratio
- 0.00
Taxes
In the past 12 months, VistaGen Therapeutics has paid 7,000 in taxes.
- Income Tax
- 7,000
- Effective Tax Rate
- -0.00
Enterprise Valuation
VistaGen Therapeutics EV to EBITDA ratio is 0.13, with an EV/FCF ratio of 0.14.
- EV to Sales
- -3.52
- EV to EBITDA
- 0.13
- EV to Free Cash Flow
- 0.14
- EV to Operating Cash Flow
- 0.14
Balance Sheet
VistaGen Therapeutics has $31.73M in cash and marketable securities with $783.00K in debt, giving a net cash position of $30.95M billion.
- Cash & Marketable Securities
- $31.73M
- Total Debt
- $783.00K
- Net Cash
- $30.95M
- Net Cash Per Share
- $0.70
- Tangible Book Value Per Share
- $0.57
Margins
Gross margin is 84.57%, with operating margin of -2784.33%, and net profit margin of -2702.64%.
- Gross Margin
- 84.57%
- Operating Margin
- -2784.33%
- Pretax Margin
- -2702.36%
- Net Profit Margin
- -2702.64%
- EBITDA Margin
- -2689.93%
- EBIT Margin
- -2720.34%
Analyst Forecast
The average price target for VistaGen Therapeutics is ―, which is 11.43% higher than the current price. The consensus rating is Neutral
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- Neutral
- Analyst Count
- 1
- Revenue Growth Forecast
- ―
- EPS Growth Forecast
- ―
Scores
- Smart Score
- ―
- AI Score
- 41
